EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current status of biological therapy use for older adults with severe asthma

Alessandra Tomasello, Alida Benfante, Lorena Gentile, Giulia Genduso, Alessia Lombardino, Dario Macaluso, Nicola Scichilone

Expert Review of Clinical Pharmacology · 2025

DOI: 10.1080/17512433.2025.2546141 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Alessandra Tomasello und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, PROMISE Department, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The management of severe asthma in older adults is an increasingly important clinical challenge. Aging-associated structural, functional, and immunological changes contribute to a distinct geriatric asthma phenotype, often marked by mixed inflammation, comorbidities, and reduced treatment responsiveness. AREAS COVERED: This review provides an overview of current biologic therapies approved for severe asthma and examines existing clinical evidence regarding efficacy, safety, and real-world outcomes in geriatric patients. Clinical challenges include the heterogeneity of asthma phenotypes in this age group, and the impact of multimorbidity and polypharmacy on treatment outcomes. EXPERT OPINION: A geriatric-centered approach to severe asthma is essential, emphasizing early initiation of biologic therapies, individualized risk-benefit analysis, and improved inclusion in research. The modulation of systemic inflammation, while carefully monitored, may bring also systemic benefits that may go beyond respiratory system. Achieving asthma remission in older adults is now a feasible goal, contingent upon proactive, tailored treatment strategies supported by more inclusive evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsBiological TherapyHumansAgedSeverity of Illness IndexPolypharmacyAge FactorsRisk AssessmentTreatment OutcomeInflammationPhenotypeMultimorbidity

Stichwörter der Autor:innen

Asthmabiologic therapiesgeriatric asthmaolder adultssevere asthma

Substanzen

Anti-Asthmatic Agents

Autor:innen und Institutionen

  • Division of Respiratory Medicine, PROMISE Department, University of Palermo, Palermo, Italy.
  • Division of Allergy, Pulmonary and Critical care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Zitieren

APA

Tomasello, A., Benfante, A., Gentile, L., Genduso, G., Lombardino, A., Macaluso, D., & Scichilone, N. (2025). Current status of biological therapy use for older adults with severe asthma. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2546141

Vancouver

Tomasello A, Benfante A, Gentile L, Genduso G, Lombardino A, Macaluso D, et al. Current status of biological therapy use for older adults with severe asthma. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2546141

BibTeX
@article{Tomasello2025,
  author = {Tomasello, Alessandra and Benfante, Alida and Gentile, Lorena and Genduso, Giulia and Lombardino, Alessia and Macaluso, Dario and Scichilone, Nicola},
  title = {Current status of biological therapy use for older adults with severe asthma},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  doi = {10.1080/17512433.2025.2546141}
}
Kostenlos starten →